title: [Clinical evaluation of effects from neo-adjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer].
abstract: Neo-adjuvant chemotherapy of epirubicin plus paclitaxel was administered to 23 patients with locally advanced breast cancer (including 13 cases of stage IIb, 6 of stage IIIa, and 4 of stage IIIb). All patients were female. They were treated with epirubicin 60 mg/m2, on day 1, by i.v. followed paclitaxel 150 mg/m2 by 3 hours continuous infusion on day 2 and every 3 weeks repeatedly. Premedication with dexamethasone, ondansetron, diphenhydramine and cimetidine were administered to prevent gastroenteric and allergic reactions before chemotherapy. Two to 4 cycles were used. Ten out of 23 patients had a complete response, 10 had partial response, and 3 had no change. The response rate was 87% (20/23). Six out of 23 patients underwent breast conserving surgery as tumor size had become smaller and downstaging was realized after neo-adjuvant chemotherapy. The major toxicities included neutropenia, myalgia, arthralgia, nephrotoxicity, gastroenteric reactions, alopecia and flushing to the face. However, these were well tolerated in these patients.
authors.affiliation: Dept. of 4th Surgery and Breast Disease Research Center, People's Hospital, Beijing University Medical School.
authors.forename: Fuzhong
authors.initials: F
authors.lastname: Tong
authors.forename: Bo
authors.initials: B
authors.lastname: Zhou
authors.forename: Deqi
authors.initials: D
authors.lastname: Yang
authors.forename: Yingming
authors.initials: Y
authors.lastname: Cao
authors.forename: Peng
authors.initials: P
authors.lastname: Liu
authors.forename: Hongjun
authors.initials: H
authors.lastname: Liu
authors.forename: Xinmin
authors.initials: X
authors.lastname: Qiao
authors.forename: Jiaqing
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D043823:Taxoids
chemical_list: D043823:Taxoids; D015251:Epirubicin; D017239:Paclitaxel